The RDH11 (retinol dehydrogenase 11) antibody is a tool used to detect and study the RDH11 enzyme, which belongs to the short-chain dehydrogenase/reductase (SDR) family. RDH11 plays a critical role in retinoid metabolism, catalyzing the oxidation of retinol (vitamin A) to retinaldehyde, a key step in visual cycle pathways and cellular differentiation processes. It is expressed in various tissues, including the retina, liver, and skin, and is localized to microsomal membranes and lipid droplets. Dysregulation of RDH11 has been implicated in metabolic disorders, retinal diseases, and certain cancers, making it a target for biochemical and biomedical research.
RDH11 antibodies are typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. These antibodies enable researchers to investigate RDH11's expression patterns, subcellular localization, and interaction partners through techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validation often includes knockout cell lines or tissue controls to confirm specificity. Commercial suppliers (e.g., Sigma-Aldrich, Abcam) provide RDH11 antibodies with detailed protocols and applications. Ongoing studies focus on its role in lipid homeostasis, cancer progression, and degenerative eye conditions, highlighting its therapeutic potential. Proper antibody selection depends on experimental needs, including species reactivity and compatibility with assay systems.